Click on headlines below to download research

Statistically significant clinical insignificance
ASIT biotech | 26/11/2019

Reported gp-ASIT+ Phase III allergy data unfortunately confirmed the outcome of the first Phase III: a statistically proven, inadequate clinical response,…

Building to a crescendo
ASIT biotech | 19/09/2019

Having reported H119 financials, ASIT’s main focus remains on the results of the second Phase III study of gp-ASIT+ for the prevention of grass pollen…

Executive Interview
ASIT Biotech | 23/07/2019

In this interview Michel Baijot, CEO of Asit…

No surprises in FY18 annual report
ASIT biotech | 17/05/2019

ASIT biotech published its preliminary FY18 results in early April, including the cash position at the end of March 2019, and issued its FY18 report in…

All the bases loaded for ASIT011
ASIT biotech | 03/04/2019

ASIT’s FY18 preliminary results were dominated by the initiation of the second Phase III study of gp-ASIT+ where randomisation is now complete. The…

Supportive data on ASIT’s short-course therapy
ASIT biotech | 14/03/2019

ASIT has announced the publication of mode of action data from its first Phase III study for its gp-ASIT+ product for grass pollen allergies. This is supportive…

Supportive data on ASIT’s short-course therapy
ASIT biotech | 06/03/2019

ASIT has announced the publication of mode of action data from its first Phase III study for its gp-ASIT+ product for grass pollen allergies. This is supportive…

Ahead of schedule on gp-ASIT+
ASIT biotech | 26/02/2019

In a transparent announcement, ASIT Biotech’s board has released the conclusions from its recent meeting. Recruitment for the pivotal Phase III study…